Member Info for Nolupus

SCoredagainsteps,

Ad you know Q1 means

1 January to the 31 of march

The meeting date itself is not the most important, it's the notification date that counts :-)

In between the meeting and the official notification , many'weeks can pass .

I personally can also envisage that IMM could wait a few days before issuing a RNS ....

The Meeting with the FDA was for Q1

I would presume that the initial meeting was to discuss the P3 trial and then after agreement on the protocol , Imm would then wait for the written confirmation to be received back before issuing the RNS

Who is to say that the FDA meeting was not held at the beginning of march ??

Read the RNS ...

Please keep factual as Speculation that has no scientific basis to it ....is worth 0

The covid 19 situation is already drastic enough

Are we not expecting News very shortly ??

7.00-7.50 :-)

7.00 - 13--19 .....the balance is at work :-)

My bets are now FULl ON ...

It does'nt take balls to buy at 7-7.5 p , it's back to where we were before the Avion deal ....

No brainer , imv

Somebody is pulling the pis. Here

But what the heck, back to the bookies :-)

Maskd2g,

You can be smug if you have.bought back in at these prices IMO

Cauldstream7,

AZ have invested hundreds of millions into Lupus research so they will not just give up , imo

Cauldstream,

Intrigued you may be :-)

IMM will inform the market of it's talks with the FDA before the end of the month or asap if the markets have calmed down , imv
The P3 approval by the FDA is in my view a sure thing ..but it will be very informative to see what they have agreed to ..

As for GSK , i cannot see them being interested in IMM as at best IMM will be tied up doing their trial for another 3 years at least :-)

Halfbutt,

My crystal ball says that News is coming shortly .....

Also from the competition ...

My ball says keep an eye on AZ

Everyone has their own agenda, but one has to keep a open mind , imv

Simple,

One should always keep an eye on the competition , imv

https://finance.yahoo.com/news/aytu-bioscience-secures-exclusive-u-120500962.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIwbbx-hHh533n628rQw3BDzhiFzn5zTvvxGz7ku-v-himJmhoUuT9AHqb-seGVRiB1q6Q-TSgZpbCUjMIGO6wC-u0a2Adq3oSZ3wZvzG3pEz1rwd7IKmTvkH7zZu_wC-_8eiyKnPbWnDjE5NyJS2xL6vIVu48dWk_PlQBSoOist

The rumour about WHO seems to be getting verified also ...

Is the rumour out of PAris

Just need a litttle Patience :-)

RNS not far off ... imo

Imm holding up despite the coronavirus ...

20-21 mill. Market cap

TwoHybrid,

Very difficult question to answer without having the details on the dosage tests that were done in the P2 trial...
I think that Imm would have after due diligence of all the clinical results seen a dosage problem or a safety problem with a higher dosage. ( just geussing )
I feel that IMM would not be doing another P3 trial if they thought that dosing is a major problem (One cannot change the dosing or frequency between trials )
As for Benlysta, one cannot compare the two...
Best regards